RFA
SNDX icon

Reilly Financial Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Reilly Financial Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,000
Closed -$45K – 1071
2021
Q1 		$45K Hold
2,000
– – ﹤0.01% 381
2020
Q4 		$44K Hold
2,000
– – ﹤0.01% 363
2020
Q3 		$30K Hold
2,000
– – ﹤0.01% 382
2020
Q2 		$30K Hold
2,000
– – ﹤0.01% 388
2020
Q1 		$22K Hold
2,000
– – ﹤0.01% 412
2019
Q4 		$18K Hold
2,000
– – ﹤0.01% 529
2019
Q3 		$15K Hold
2,000
– – ﹤0.01% 567
2019
Q2 		$19K Hold
2,000
– – ﹤0.01% 553
2019
Q1 		$11K Hold
2,000
– – ﹤0.01% 669
2018
Q4 		$9K Buy
+2,000
New +$11K ﹤0.01% 668

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Reilly Financial Advisors's SNDX Position: Q2 2021 in Review

Reilly Financial Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q2 2021, closing a stake of 2,000 shares — an estimated $45K sold.

Reilly Financial Advisors first reported a position in SNDX in Q4 2018 and held it in 10 quarters. The position peaked at $45K in Q1 2021. 115 funds tracked by Wall St. Rank hold SNDX as of Q2 2021.

  • Reilly Financial Advisors reported no remaining Syndax Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Reilly Financial Advisors sold 2,000 Syndax Pharmaceuticals shares in Q2 2021, an estimated $45K.
  • Reilly Financial Advisors first reported a position in Syndax Pharmaceuticals in Q4 2018 and held it in 10 quarters.
  • Reilly Financial Advisors's Syndax Pharmaceuticals position peaked at $45K in Q1 2021.
  • 115 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2021.

Based on Reilly Financial Advisors's 13F filing for Q2 2021, filed 3 Aug 2021.